A pooled analysis of 86 patients treated with PD-1 blockade alone and 35 patients treated with combined ipilimumab suggested that the combination has a greater efficacy than the monotherapy with a similar safety profile (19) for unresectable or advanced MM. Here, PDCD1 is linked to Miyoshi myopathy.